tbuckley/cabot-search huggingface dataset:
Clinical significance of diffusion-weighted whole body magnetic resonance imaging with background body signal suppression (DWIBS) as a staging procedure for lymphoma patients in comparison with FDG-PET
Authors: T. Itoyama, T. Shibuya, T. Koga, M. Kitagawa, T. Yoshida, H. Kobayashi, A. Utsunomiya, R. Ochiai
Journal: Journal of Clinical Oncology (2007)

8084 Background: FDG-PET is thought to be an important staging tool in lymphomas. However, high cost and exposure to radioactive agents are of disadvantage. Diffusion weighted whole body magnetic resonance imaging with background body signal suppression (DWIBS) is recently reported to be a new way of magnetic resonance imaging which can make FDG-PET-like imaging possible to detect tumors (Takahara et al; Radiation Medicine 22: 275–282, 2004). This study is aimed to compare accuracy and clinical significance of DWIBS to FDG - PET. Methods: We examined 19 lymphoma (Ly) patients (pts) by using both DWIBS and FDG -PET at the time of diagnosis before therapy. There were follicular Ly in 3 pts, nodal marginal zone Ly in 1, diffuse large B-cell Ly in 9 including primary stomach Ly in 2, peripheral T -cell Ly in 4, and MALT Ly of stomach (GI-MALT) in 2. DWIBS was performed with a 1.5 -Tesla system as previously reported (Ochiai et al; Nichidoku -Iho 50: 86–98, 2005). Clinical staging was made according to the Ann Arbor classification. Results: Both DWIBS and FDG -PET had positive findings in 18 of 19 pts except for a case of GI -MALT. In nodal lesions, DWIBS was positive in 16 pts at 66 sites compared to 16 pts at 68 sites with FDG -PET. DWIBS was negative in 3 pts at 5 sites in spleen, hilar and mediastinal lymphnodes where positive in FDG -PET. DWIBS was positive in 2 pts at 4 sites in iliac and inguinal lymphnodes that are negative in FDG -PET. In extranodal lesions, DWIBS was positive in 12 pts at 17 sites as compared to 12 pts at 18 sites with FDG -PET. Involvement of bone and stomach were equally identified at 8 sites. DWIBS was negative in 2 pts at 2 sites in liver and pleura with FDG -PET positive. Small skin lesions were clearly identified on DWIBS. Discordance of clinical staging was not observed between DWIBS and FDG -PET. Conclusions: Although some discrepancy was seen between DWIBS and FDG -PET, there was no disadvantage of DWIBS compared to FDG -PET. Furthermore, DWIBS has no risk of radiation exposure and is even advantageous to detect lesions with FDG -PET negative. We conclude DWIBS is a new useful tool to assess tumor spread in lymphomas. No significant financial relationships to disclose.
Inhibitors Of Src Family and AKT Regulate The Activity Of CD20 Promoter
Authors: Beata Pyrzynska, Kamil Bojarczuk, Magdalena Winiarska, Jacek Bil, Nina Miazek, Piotr Zapala, Malgorzata Bobrowicz, Michal Dwojak, Marta Siernicka, Jakub Golab
Journal: Blood (2013)
TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis
Authors: Daniel R. Principe, Brian DeCant, Emman Mascariñas, Elizabeth A. Wayne, Andrew M. Diaz, Naomi Akagi, Rosa Hwang, Boris Pasche, David W. Dawson, Deyu Fang, David J. Bentrem, Hidayatullah G. Munshi, Barbara Jung, Paul J. Grippo
Journal: Cancer Research (2016)

In early pancreatic carcinogenesis, TGFβ acts as a tumor suppressor due to its growth-inhibitory effects in epithelial cells. However, in advanced disease, TGFβ appears to promote tumor progression. Therefore, to better understand the contributions of TGFβ signaling to pancreatic carcinogenesis, we generated mouse models of pancreatic cancer with either epithelial or systemic TGFBR deficiency. We found that epithelial suppression of TGFβ signals facilitated pancreatic tumorigenesis, whereas global loss of TGFβ signaling protected against tumor development via inhibition of tumor-associated fibrosis, stromal TGFβ1 production, and the resultant restoration of antitumor immune function. Similarly, TGFBR-deficient T cells resisted TGFβ-induced inactivation ex vivo, and adoptive transfer of TGFBR-deficient CD8(+) T cells led to enhanced infiltration and granzyme B-mediated destruction of developing tumors. These findings paralleled our observations in human patients, where TGFβ expression correlated with increased fibrosis and associated negatively with expression of granzyme B. Collectively, our findings suggest that, despite opposing the proliferation of some epithelial cells, TGFβ may promote pancreatic cancer development by affecting stromal and hematopoietic cell function. Therefore, the use of TGFBR inhibition to target components of the tumor microenvironment warrants consideration as a potential therapy for pancreatic cancer, particularly in patients who have already lost tumor-suppressive TGFβ signals in the epithelium. Cancer Res; 76(9); 2525-39. ©2016 AACR.
Weekly topotecan and cisplatin (TOPOCIS) as neoajuvant chemotherapy for locally-advanced squamous cervical carcinoma: results of a phase II study
Authors: F. Zanaboni, B. Grijuela MD, S. Kusamura, A. Ditto, F. Hanozet, R. Fontanelli, E. Solima, F. Martinelli, A. Bomè, F. Raspagliesi
Journal: Journal of Clinical Oncology (2008)

16500 Background: Concomitant chemoradiation is the treatment of choice for locally advanced cervical cancer. Neoadjuvant chemotherapy has been proposed as an alternative, and a 14% absolute improvement in survival has been described. Methods: Since October 2006, 22 patients were enrolled in this single institution prospective phase II study. Eligibility criteria were: squamous or adenosquamous cervical carcer; stages IB2, IIA, IIB; ECOG performance status ≤2; neutrophil count ≥1,500/μL; platelet count ≥100,000/μL, normal renal and liver function. Treatment consisted of 6 weekly courses of Topotecan (2 mg/m2) and Cisplatin (40 mg/m2). All responsive and stable patients were submitted to radical surgery, while progressed cases underwent definitive radiotherapy. The primary end point was to evaluate the efficacy and toxicity of weekly TOPOCIS in locally-advanced squamous cervical cancer. Results: Mean age of patients was 49 years (35- 64). Clinical FIGO Stage: 2 IB2; 3 IIA; 17 IIB. Histotype: squamous in 20 and adenosquamous in 2. G1: 1, G2: 13, G3: 8. Thirty-six percent of patients had suspicious lymph node metastases at MRI. Ninety-one percent of patients received the planned 6 courses and 82% of cycles were delivered at a full dose and without delay. Treatment was well tolerated and no death occurred. G3-G4 bone marrow toxicity was observed in 5% of cycles. Three cases required blood transfusions; 3 cases, G-CSF; and 1 case, erythropoietin. Clinical response rate was 82%. One progressive case was irradiated, while the others were submitted to radical hysterectomy + pelvic ± para-aortic lymphadenectomy. Overall pathological response rate was 95%, with 24% of optimal pathologic responders (complete response or microscopic partial response). Twenty-nine percent of patients presented lymph node metastases. Forty-seven percent of patients received adjuvant radiotherapy because of positive surgical margins, vaginal or nodal involvement. Median follow up is 6 months and all patients are free from disease recurrence. Conclusions: Weekly Topotecan and Cisplatin as neo-adjuvant chemotherapy in locally-advanced cervical cancer showed an acceptable toxicity and a promising response rate. No significant financial relationships to disclose.
Hydrazine sulfate in nonsmall-cell lung cancer.
Authors: J Gold
Journal: Journal of Clinical Oncology (1990)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1990.8.6.1117 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2161450 Hydrazine sulfate in nonsmall-cell lung cancer. J GoldxJ GoldSearch for articles by this author https://doi.org/10.1200/JCO.1990.8.6.1117 PDF "Hydrazine sulfate in nonsmall-cell lung cancer.." Journal of Clinical Oncology, 8(6), pp. 1117–1118© 1990 by American Society of Clinical Oncology
Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head is justified in elderly patients: A Retrospective Cohort Study
Authors: Bernhard W. Renz, Philippe N. Khalil, Michael Mikhailov, Sandra Graf, Tobias S. Schiergens, Hanno Niess, Stefan Boeck, Volker Heinemann, Werner Hartwig, Jens Werner, Christiane J. Bruns, Axel Kleespies
Journal: International Journal of Surgery (2016)
Features of the Bronchial Bacterial Microbiome Associated with Allergy and Mild Allergic Asthma.
Authors: Juliana Durack, Susan V. Lynch, Avraham Beigelman, Mario Castro, Elliot Israel, Monica Kraft, David Mauger, Richard Martin, Snehal Nariya, Steven R. White, Homer A. Boushey, Yvonne Huang
Journal: Journal of Allergy and Clinical Immunology (2016)
C-Type Tumor Virus Particles in Salivary Tissue of Domestic Cats&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: M B Gardner, R W Rongey, E Y Johnson, R DeJournett, R J Huebner
Journal: JNCI Journal of the National Cancer Institute (1971)

C-type RNA tumor virus particles were observed by electron microscopy in the submaxillary gland, parotid gland, and bone marrow tissues from almost every domestic cat with spontaneous fymphoma and fibrosarcoma induced by feline sarcoma virus. C-type particles were less f.requent in these tissues from cats with severe cnemic, spontaneous sorcoma, or infectious peritonitis and were not seen in normal cats. Whether this finding is significant in the propagation and natural spread of this virus is unknown.
P0590 : Modified model for end stage liver disease score accurately predicts death or liver transplantation in acute flares of chronic hepatitis B
Authors: J. Fung, F. Lam, K. Chok, W.-K. Seto, T. Wong, A. Chan, S.-C. Chan, C.-L. Lai, C.-M. Lo, M.-F. Yuen
Journal: Journal of Hepatology (2015)
Yolk Sac Macrophages, Fetal Liver, and Adult Monocytes Can Colonize an Empty Niche and Develop into Functional Tissue-Resident Macrophages
Authors: Lianne van de Laar, Wouter Saelens, Sofie De Prijck, Liesbet Martens, Charlotte L. Scott, Gert Van Isterdael, Eik Hoffmann, Rudi Beyaert, Yvan Saeys, Bart N. Lambrecht, Martin Guilliams
Journal: Immunity (2016)
NRG-LU001: A phase II trial investigating metformin as a chemo-radio-sensitizer in locally advanced non-small cell lung cancer (NSCLC)
Authors: Theodoros Tsakiridis, Chen Hu, Heath Skinner, Rafael Santana-Devila, Bo Lu, Jeremy Erasmus, Anthony Doemer, Jeffrey Bradley
Journal: Journal of Thoracic Oncology (2016)
Abstract P291: Anger Expression and Risk of Stroke Subtypes: The Circulatory Risk in Communities Study (CIRCS)
Authors: Tetsuya Ohira, Takeshi Tanigawa, Hironori Imano, Akihiko Kitamura, Masahiko Kiyama, Kazumasa Yamagishi, Tomoko Sankai, Renzhe Cui, Takeo Okada, Yoshinori Ishikawa, Hiroyasu Iso
Journal: Circulation (2012)

Background: Previous studies have reported that anger expression style is associated with cardiovascular disease and its risk factors. Epidemiologic data regarding the association between anger expression and risk of stroke have been inconsistent, and few studies have reported the association of anger expression with stroke subtypes. Hypothesis: We assessed the hypothesis that suppressed anger is associated with increased risk of stroke, and the associations vary by stroke subtype. Methods: A prospective study of Japanese subjects aged 30–74 years was undertaken using data collected from 6,276 participants (2,285 men and 3,991 women) in cardiovascular risk surveys conducted in four communities between 1995 and 1998. We used the Spielberger Anger Expression Scale to measure self-reported levels of anger expression style; anger expressed outwardly is regarded as “anger-out” and anger held in or suppressed is classified as “anger-in.” The incidence of stroke was ascertained by systematic surveillance. The hazard ratios (HRs) of incidence of stroke and its subtypes and 95% confidence intervals (CI) relative to the lowest tertile of anger expression were calculated with adjustment for age and other potential confounding factors using the Cox proportional hazards model. Results: During an average follow up of 9.1-years, 129 incident strokes (50 hemorrhagic, 77 ischemic, and 2 unclassified strokes) occurred. Men with “anger-in” scores in the highest tertile had a 1.7-fold multivariable-adjusted relative risk of stroke as compared with those in the lowest tertile, but it did not reach statistical significance (HR; 1.73, 95% CI; 0.94–3.19, p=0.08). When stratifying for stroke subtypes, the associations between “anger-in” and stroke tended to be stronger for hemorrhagic stroke than ischemic stroke; HRs (95% CI) were 3.82 (1.03–14.1) for hemorrhagic stroke and 1.32 (0.64–2.71) for ischemic stroke. Anger-in score was not associated with incidence of either hemorrhagic or ischemic stroke in women. In men and women, there were no significant associations between “anger-out” and incidence of stroke. As compared with the lowest tertile of “anger-out” scores, the multivariable-adjusted HRs of stroke for the highest tertile of “anger-out” scores were 1.39 (0.74–2.59) for men and 1.48 (0.78–2.78) for women, respectively. Conclusions: Suppressed anger may be associated with increased risk of hemorrhagic stroke among middle-aged Japanese men, but not women.
Gulf war illness
Authors: P. Beale, P. Heaf, N. Jones
Journal: BMJ (1997)

Gulf war illness Why it took so long to decide to investigateEditor-As it is now six years since the Gulf war, it is reasonable to ask why the problem of Gulf war syndrome has not been resolved. 1 As surgeon general in 1991-4 I want to comment on the unravelling timetable during these six years.At no time have we denied that Gulf veterans have been ill-indeed, whenever possible we have actively recommended their appropriate medical management.Secondly, despite press reports, we have always kept an open mind on the presence of a specific Gulf war syndrome.The Gulf conflict in 1990-1 itself was short, casualties mercifully few, and the sickness rates unremarkable; likewise, when troops returned to the UK the daily sickness rate did not increase.Also at that stage little evidence existed of psychiatric illness or post-traumatic stress syndrome.Some 18 to 24 months later, however, we became aware of a campaign by lawyers to recognise a specific Gulf illness.Up to 200 people were on their books, but despite widespread appeals for them to come forward, including two television appeals, only 15 approached the armed forces medical services.Not surprisingly, among these 15 no pattern of illness emerged.They were all managed appropriately.As we were keen to solve the problem, in October 1993 we appointed a single consultant physician, Group Captain Coker, to see all such patients.At first only a trickle of patients came forward-even by June 1994 (three and half years later) he had seen only 30 patients.Over the next two years, however, these numbers increased so that by January 1997, 1100 had been registered, 920 had been seen and fully investigated, and results had been completed and analysed in 519.A preliminary paper in the summer of 1996 concluded: "From our small database it would not appear that there is a unique cluster of symptoms which would suggest a new pattern of illness in veterans." 2 There was, however, a higher than normal incidence of psychiatric and stress related illness.A large battery of tests was uniformly performed on all the patients, with further investigations as necessary.Now it has been agreed that full epidemiological studies are to be undertaken into the incidence of ill health among UK Gulf war veterans and into their reproductive health.In answering the criticism that these expensive studies should have been instigated earlier, I have tried to show how difficult it has been to decide exactly when this decision could have been made.Early on there were very few patients and no evidence of a syndrome.At all stages we have liaised with our counterparts in the United States.They embarked a little earlier on similar studies as they had similar results to their investigations but dealt with greater numbers.An important reason for writing this letter is because our armed forces may well be placed in similar alien environments in future and we owe it to them to provide the best medical support, which of course includes planned protective and scientifically justified measures against likely threats to their health.
Determinants of therapeutic resistance in glioblastomas: Lessons learned from RTOG 0211 and beyond.
Authors: A. Chakravarti, M. Wang, H. Robins, A. Guha, W. J. Curran, D. Brachman, A. K. Choucair, M. Dolled-Filhart, T. Lautenschlaeger, M. P. Mehta
Journal: Journal of Clinical Oncology (2010)

2062 Background: Activation of the epidermal growth factor receptor (EGFR) pathway has been implicated with mediating treatment resistance in GBMs. Objectives: 1. To identify a subset of GBM patients who may benefit from the addition of gefitinib to RT versus RT alone through molecular profiling. 2. Using preclinical models, to identify strategies to overcome putative resistance mechanisms to both RT alone and RT + gefitinib identified from the correlative clinical study. Methods: RTOG 0211 was a phase I/II study, with 31 patients enrolled for phase I and 147 patients for phase II. Tissue microarrays (70 cases from RTOG 0211, 112 from historical controls) were used for clinical molecular correlative analysis. Results: There was no median overall survival benefit for patients treated with gefitinib + RT versus RT alone. Younger age was significantly associated with better outcome (HR [50+ vs. < 50] = 1.86, (95%CI: 1.22-2.83; p = 0.0037) in RTOG 0211-treated patients. After adjusting for age, higher levels of SRC and IGFR1 were associated with adverse overall survival in RTOG 0211-treated patients. Of cautionary note, GBM patients with elevated levels of SRC and PTEN appeared to have significantly improved overall survival if treated by RT alone versus RT + gefitinib. Patients with lower levels of PTEN appeared to demonstrate a trend towards improved clinical outcome in the setting of RT + gefitinib versus RT alone. Addition of SRC inhibitors in the context of high SRC expression or overexpression of PTEN in the context of low PTEN expression could restore a therapeutic benefit of gefitinib in preclinical models. Conclusions: The addition of gefitinib to RT does not appear to benefit the general, unselected population of GBM patients. Of cautionary significance, our findings reveal biomarker profiles that predict for worse outcome in the setting of combined gefitinib + RT versus RT alone. Supported by the NIH/NCI awards RO1CA108633; RC2CA148190; and the Brain Tumor Funders Collaborative Group. Also supported by RTOG U10 CA21661 and CCOP U10 CA37422 grants from the NCI. This abstract's contents are the sole responsibility of the authors and do not necessarily represent the official views of the NCI. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pharmacyclics Adnexus, Schering-Plough, Genentech, TomoTherapy Pharmacyclics, Pharmacyclics, Tomotherapy, TomoTherapy Genentech, Schering, Genentech, Schering-Plough
Prognostic value of thymidylate synthase and cox-2 expression in colorectal cancer patients' tumors
Authors: M. Aliustaoglu, M. Gumus, A. Midi, C. A. Celikel, M. Ekenel, F. Yumuk, G. Basaran, N. S. Turhal
Journal: Journal of Clinical Oncology (2004)

3731 Background: Colorectal cancer (CRC) is a major health problem in the world for both men and women due to its high incidence and limited benefit with chemotherapy when the disease recurs. There is a need for progress in assessment of the prognosis of patients and predict who would benefit from treatment. In this study, the value of molecular markers thymidylate synthase (TS) and cox-2 were evaluated as prognostic predictors in patients with stage II and III CRC. Patients and Methods: We retrospectively analyzed the prognostic value of TS and cox-2 in 49 patients with stage II (n=23) and III (n=26) CRC. They were treated with either surgery alone or surgery followed by adjuvant fluorouracil and leucovorin chemotherapy in Marmara University Hospital, Medical Oncology Department between April 1997 and 2003. A specialized pathologist evaluated these markers using immunohistochemical techniques. Samples were scored as high and low TS and Cox-2 intensity according to their staining properties.Low intensity: No staining or less than 10% of tumoral cells are stained. High intensity: More than 10% of tumoral cells are stained. Results: High TS intensity was found in 20.4% of tumor samples with mucinous component and in 64.1% without mucinous component (p=0.01). In patients whose tumor samples had low or high TS intensity 5 year overall survival was 61.5% and 37.5% respectively (p=0.86). Also with low or high cox-2 intensity, overall 5-year survival did not improved (40% vs 70.6%) statistically (p=0.72). More patients with high TS staining tumors relapsed compared to those with low TS staining (p=0.01). Conclusions: Although we did not find a significant relationship between TS, cox-2 and overall survival, statistically significant RFS rates are suggestive of a correlation if these markers are studied in a greater sample size. No significant financial relationships to disclose.
The CDC Guideline on Opioid Prescribing
Authors: Yngvild Olsen
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal